Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD Regimen in Primary Central Nervous System Lymphoma
NCT04688151Phase 1Completed
- Sponsor
- National Health Research Institutes
- Start
- Feb 2021
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of acalabrutinib tablet (Variant 1) in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by National Health Research Institutes. Primary endpoint: Maximum Tolerated Dose of acalabrutinib at 28 weeks. Started Feb 2021; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04688151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688151.